Merck is racing to defend its leadership in the market for cancer drugs ahead of Keytruda’s looming patent cliff. A clinical ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.

Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the ...

Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Merck’s MRK stock has declined 7.3% in the past month despite announcing a solid first-quarter 2026 report on April 30. Merck beat estimates for both earnings and sales. Total r ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Merck and Eisai are looking at an investigational ...

On the Wednesday, April 15, 2026, episode of The Excerpt podcast: Prices for cutting-edge medical treatments can balloon in the U.S. health care system, leading to higher costs for the employer, ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...